More Business Wire
View Older Stories View Newer Stories-
Kaname Capital Renews Demand for Independent Third-Party Investigation at Fukuda Denshi; Sets May 29 Deadline Ahead of June 26 AGM
-
Aberdeen Investments and DigitalBridge Acquire Equans Infra & Mobility, B.V.
-
Boomi Named One of The Sunday Times Best Places to Work 2026
-
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services
-
ISAP2026 - The 18th International Forum for Sustainable Asia and the Pacific
-
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases
-
Outcome of Innate Pharma’s 2026 Annual General Meeting
-
Global Stars Ahn Hyo-seop and Khalid Release New Cross-Market Single “Something Special” via FANDOM Today
-
Mitsubishi Electric Engineer Earns Kaggle Competitions Master Title in World’s Largest AI Competition
-
iA Financial Group Announces Offering of $500 million of 4.158% Fixed/Floating Unsecured Subordinated Debentures
-
InterSystems Expands Indonesia Presence with Jakarta Office
-
More Than Half of Japanese Companies are Increasing AI Infrastructure Investment According to the 2026 Wasabi Global Cloud Storage Index
-
Lenovo Group: Q4 and Full Year Financial Results 2025/26
-
Jeremiah Smith Appointed to Sierra College Foundation Board of Directors
-
Burtech Acquisition Corp II Announces Pricing of $80,000,000 Initial Public Offering
-
KBRA Assigns Preliminary Ratings to J.P. Morgan Mortgage Trust 2026-4MPR (JPMMT 2026-4MPR)
-
Global Real Assets Trust Announces Filing of Final Prospectus for Offering of Preferred Units
-
Lightmatter Unveils Guide DR: Industry First Liquid-Cooled Laser NIC that Quadruples Rack Density
-
Zai Lab Announces Changes to Senior Leadership Team
-
KBRA Assigns AA- Rating to Miami-Dade County, FL Aviation Revenue Refunding Bonds; Outlook Positive
-
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
-
Conduent Announces Agreement to Sell Its Public Transit Business to Modaxo for $164 Million
-
Halliburton Announces Dividend
-
MSCI Announces Dates for 2026 Annual Market Classification and Accessibility Reviews
-
FCPT Announces Acquisition of a Gerber Collision Property for $3.5 Million
-
80% of Individual Contributors Say Their Manager’s Approach to AI is Hands-Off, FranklinCovey Research Finds
-
Logitech Files Annual Report on Form 10-K
-
Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting
-
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
-
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
-
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
-
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
-
Dell Technologies to Present at Investor Conference in June
-
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
-
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
-
A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Canc
-
858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting
-
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer
-
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
-
Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026
-
Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026
-
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
-
Ingenia Therapeutics, a Clinical-Stage Biotechnology Company, Has Received Approval for an Initial Public Offering on the Korea Exchange (KRX)
-
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
-
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
-
City of Hope Researchers Present Advances in Targeted Therapies, Microbiome Science and Blood Cancers at ASCO 2026
-
Daytona International Speedway to Install State-of-the-Art Musco LED Lighting System, Setting New Global Standard for Motorsports Venues
-
Mayville Engineering Company Announces Closing of Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares of Common Stock
-
Hour Children and Mental Health Innovations Teams Win Morgan Stanley’s 2026 Strategy Challenge Supporting Nonprofits in the U.S. and the UK
-
Matador Resources Company Announces Successful Acquisitions in Federal Lease Sale
